Evidence map›Paper›PMID 28651593›Full record

ArticleVirology journal2017

Maternal antibodies protect offspring from severe influenza infection and do not lead to detectable interference with subsequent offspring immunization.

Joan E M van der Lubbe, Jessica Vreugdenhil, Sarra Damman, Joost Vaneman, Jaco Klap, Jaap Goudsmit, Katarina Radošević, Ramon Roozendaal

Abstract read
In one paragraph

Article in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Influenza in High-Risk Hosts-Lessons Learned from Animal Models.Cold Spring Harbor perspectives in medicine · 2020
    Review
  9. Protective Effect of Recombinant Proteins ofFrontiers in cellular and infection microbiology · 2020
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joan E M van der LubbeJanssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN, Leiden, The Netherlands. Jvander7@its.jnj.com.
Jessica VreugdenhilJanssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN, Leiden, The Netherlands.
Sarra DammanJanssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN, Leiden, The Netherlands.
Joost VanemanJanssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN, Leiden, The Netherlands.
Jaco KlapJanssen Prevention Center, Center of Excellence of Janssen Research & Development, Pharmaceutical companies of Johnson and Johnson, Leiden, The Netherlands.
Jaap GoudsmitJanssen Prevention Center, Center of Excellence of Janssen Research & Development, Pharmaceutical companies of Johnson and Johnson, Leiden, The Netherlands.
Katarina RadoševićPresent address: Sanofi, Biologics Research, Vitry-sur-Seine, France.
Ramon RoozendaalJanssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 4-6, 2333CN, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVarious studies have shown that infants under the age of 6 months are especially vulnerable for complications due to influenza. Currently there are no vaccines licensed for use in this age group. Vaccination of pregnant women during the last trimester, recommended by the WHO as protective measure for this vulnerable female population, may provide protection of newborns at this early age. Although it has been observed that maternal vaccination can passively transfer protection, maternal antibodies could possibly also interfere with subsequent active vaccination of the offspring.

methodsUsing a mouse model, we evaluated in depth the ability of maternal influenza vaccination to protect offspring and the effect of maternal immunization on the subsequent influenza vaccination of the offspring. By varying the regimen of maternal immunization we explored the impact of different levels of maternal antibodies on the longevity of these antibodies in their progeny. We subsequently assessed to what extent maternal antibodies can mediate direct protection against influenza in their offspring, and whether these antibodies interfere with protection induced by active vaccination of the offspring.

resultsThe number of immunizations of pregnant mice correlates to the level and longevity of maternal antibodies in the offspring. When these antibodies are present at time of influenza challenge they protect offspring against lethal influenza challenge, even in the absence of detectable HAI titers. Moreover, no detectable interference of passively-transferred maternal antibodies on the subsequent vaccination of the offspring was observed.

conclusionIn the absence of a licensed influenza vaccine for young children, vaccination of pregnant women is a promising measure to provide protection of young infants against severe influenza infection.

Indexed as

Immunity, Maternally-AcquiredAnimalsDisease Models, AnimalInfluenza VaccinesMiceOrthomyxoviridae InfectionsSurvival AnalysisInfluenza VaccinesInfluenza virusMaternal antibodiesPassive protectionPlacental transferProtectionSeasonal influenza vaccinationVaccination during pregnancyVaccination gap

Identifiers

PMID28651593
PMCPMC5485558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.